Trends in drug development

1. Trends in drug
development
RECENT ADVANCES IN BIOTECHNOLOGY
Dr. Hafiz Mamoon Rehman
Det. Biotechnology

2. GROUP NO.7
MEMBERS COUNT:12
 Hafiza Bushra Akram (2017-ag-3345)
 Farwa Yaqub (2021-ag-1777)
 M. Sohaib Iftikhar (2021-ag-1887)
 Maiyda Shafiq (2021-ag-1834)
 Amna Rubbani (2021-ag-1810)
 Ammara Khan (2021-ag-1919)
 Asma Rasheed (2021-ag-286)
 Furqan Tayyab (2021-ag-2186)
 Ghalia Nadeem (2021-ag-2160)
 Riffat Malik (2021-ag-2184)
 Farah Naaz (2017-ag-8444)
 Momna Khalid (2017-ag-8426)

3. INTRODUCTION
 Drug is a chemical substance which produces a biological effect when administered.
 In 1891, Paul Elrich found antimalarial effects of methylene blue. Father of modern
chemotherapy and developed first synthetic drug.
Drug discovery involves validation and identification of a disease target.
Drug Development is a process for finding useful pharmaceuticals and turning them
into medicine.
 Drug discovery approaches involve i.e., Structure based and Target based.
(Furqan, Asma, Ammara)

4. DRUG UTILIZATION
 Drug prescription includes superscription, inscription,
subscription, signature.
 Targets for drug action- receptors, ion channels, enzymes,
carrier molecule.
 Drug routes ( IV, IM, SC, orally etc.)
 Dosage forms i.e. solid (capsules, tablets) & liquid
(emulsions, gels).
(Ghalia, Amna, Maiyda)

5. Drug discovery and development
 Recent technique: computer aided drug design (Riffat, Farwa, Sohaib)

6. CONCLUSION
The advancement of medications incorporates, the way things are assimilated, dispersed,
utilized, discharged and its possible advantages and systems of activity.
 Drug use focuses around the different clinical, social, and financial parts of medication use. It
includes the dangers and advantages of medication treatment, while social angles can be
connected with improper use.
Current focus is on applied technology: must understand the drug discovery process
 Drug disclosures incorporates, new advancements, for example, those that give method for
focusing on clinical items to explicit destinations inside the body or to control hereditary material.
(Bushra, Momna, Farah)

7. • Shen, W. W. (1999). A history of antipsychotic drug development. Comprehensive psychiatry, 40(6), 407-
414.
• Senn, S. S. (2008). Statistical issues in drug development (Vol. 69): John Wiley & Sons.
• DiMasi, J. A. (1995). New drug development: Cost, risk, and complexity. Drug Information, 29(2), 375-384.
• Hansen, R., & Chien, R. (1979). The pharmaceutical development process: estimates of current development
costs and times and the effects of regulatory changes. Issues in Pharmaceutical Economics. In: Lexington
Books, Lexington, MA.
• DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991). Cost of innovation in the
pharmaceutical industry. Journal of health economics, 10(2), 107-142.
• Wardell, W. M., DiRaddo, J., & Gene Trimble, A. (1980). Development of new drugs originated and
acquired by United States–owned pharmaceutical firms, 1963–1976. Clinical Pharmacology &
Therapeutics, 28(2), 270-277.
REFERENCES

8. • Mohd, A., & Jyoti, D. A. INTERNATIONAL RESEARCH JOURNAL OF PHARMACY.
• Siddharthan, N., Prabu, M. R., & Sivasankari, B. (2016). Bioinformatics in Drug Discovery
a Review. International Journal of Research in Arts and Science, 2(2), 11-13.
• Frantz, S., & Smith, A. (2003). New drug approvals for 2002. Nat Rev Drug Discov, 2(2),
95-96.
• Ma, C., Peng, Y., Li, H., & Chen, W. (2021). Organ-on-a-chip: a new paradigm for drug
development. Trends in pharmacological sciences, 42(2), 119-133.
• Dugger, S. A., Platt, A., & Goldstein, D. B. (2018). Drug development in the era of
precision medicine. Nature Reviews Drug Discovery, 17(3), 183-196.
doi:10.1038/nrd.2017.226
• Chen, X., Jorgenson, E., & Cheung, S. T. (2009). New tools for functional genomic
analysis. Drug discovery today, 14(15-16), 754-760.